2-(N-tert-Butylaminomethyl)benzimidazol | 66551-10-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 2-(N-tert-Butylaminomethyl)benzimidazol
• 英文别名: (1H-benzoimidazol-2-ylmethyl)-tert-butyl-amine；N-(1H-benzimidazol-2-ylmethyl)-2-methylpropan-2-amine
• CAS: 66551-10-8
• 化学式: C₁₂H₁₇N₃
• mdl: MFCD13176429
• 分子量: 203.287
• InChiKey: HXUGYLXGETWCLX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.416
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Cannabinoid receptor ligands and uses thereof
  申请人：Pfizer Inc.

  公开号：US20040214837A1

  公开（公告）日：2004-10-28

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. 1

  本文描述了作为大麻素受体配体的化合物（I）及其在治疗与动物体内大麻素受体介导相关疾病中的用途。
• ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE
  申请人：Li Xiaoming

  公开号：US20080194545A1

  公开（公告）日：2008-08-14

  The present invention is directed to compounds of formula I, pharmaceutical compositions comprising the compounds, and methods for making and using the inventive compounds.

  本发明涉及式I的化合物，包括该化合物的药物组合物，以及制备和使用该创新化合物的方法。
• Dihydropyrancarboxamides and uses thereof
  申请人：Schreiber L. Stuart

  公开号：US20080070916A1

  公开（公告）日：2008-03-20

  The present invention provides novel dihydropyrancarboxamide compounds of formula (I): and collections of these compounds, and provides methods for the synthesis of these compounds; wherein R 1 -R 6 are as defined herein. Additionally, the present invention provides pharmaceutical compositions and methods for treating disorders such as proliferative diseases, and cancer, to name a few.

  本发明提供了式（I）的新型二氢吡嗪羧酰胺化合物以及这些化合物的集合，并提供了合成这些化合物的方法；其中R1-R6如本文所定义。此外，本发明还提供了治疗增生性疾病和癌症等疾病的药物组合物和方法。
• Androgen Receptor Modulators
  申请人：Wang Jiabing

  公开号：US20070269405A1

  公开（公告）日：2007-11-22

  Compounds of structural Formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

  结构式（I）的化合物以组织选择性的方式调节雄激素受体（AR），在增强肌肉张力和治疗由雄激素缺乏引起的或可以通过雄激素治疗改善的疾病中有用，包括骨质疏松症，骨质疏松症，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建手术后的骨损伤，肌肉萎缩，虚弱，老化皮肤，男性性腺功能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖症，再生障碍性贫血和其他造血系统疾病，炎性关节炎和关节修复，艾滋病浪费，前列腺癌，良性前列腺增生症（BPH），腹部脂肪堆积，代谢综合征，2型糖尿病，癌症恶病质，阿尔茨海默病，肌肉萎缩症，认知能力下降，性功能障碍，睡眠呼吸暂停，抑郁症，早发卵巢衰竭和自身免疫疾病，单独或与其他活性药物联合使用。
• CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
  申请人：Griffith A. David

  公开号：US20070275964A1

  公开（公告）日：2007-11-29

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.

  本文描述了化学式为(I)的化合物，它们作为大麻素受体配体并在动物中治疗与大麻素受体介导相关的疾病中的用途。